{"id":"W2489765770","doi":"10.1200/jco.2013.31.15_suppl.8034","title":"Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Pemetrexed; Internal medicine; Clinical endpoint; Lung cancer; Placebo; Population; non-small cell lung cancer (NSCLC); Bevacizumab; Intention-to-treat analysis; Phases of clinical research; Hazard ratio; Surgery; Gastroenterology; Adverse effect; Oncology; Randomized controlled trial; Chemotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002526297,0.002427497,0.002490888,0.0007031923,0.0005003196,0.001098614,0.001373105,0.001877256,0.006599349],"category_scores_gemma":[0.001508464,0.001059351,0.001557334,0.0004348379,0.001417589,0.001236069,0.0004643396,0.003354375,0.001372056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000833828,"about_ca_system_score_gemma":0.001553223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009390917,"about_ca_topic_score_gemma":0.003102229,"domain_scores_codex":[0.9994441,0.0003280787,0.0000251812,0.00008515433,0.00003692199,0.00008064211],"domain_scores_gemma":[0.9992512,0.0001821046,0.0001505679,0.00004248003,0.00003977309,0.0003339049],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9536202,0.02297473,0.0007457151,0.0005917012,0.0006721566,0.00005721553,0.00007786902,0.0004727172,0.005832293,0.0001447717,0.001265948,0.01354468],"study_design_scores_gemma":[0.9297152,0.06802972,0.0009039446,0.00001325116,0.000158236,0.00002411602,0.00001278739,0.0002764096,0.0003653601,0.0000747866,0.0004162392,0.000009857667],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768428,0.003930184,0.00122838,0.0009550253,0.0007277019,0.01108412,0.002080484,0.0003028099,0.002848584],"genre_scores_gemma":[0.9715841,0.002991861,0.003032013,0.002002263,0.0005705667,0.01160715,0.002095809,0.00006332983,0.006052918],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006599349,"threshold_uncertainty_score":0.02207696,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03439827634792551,"score_gpt":0.4187136529175101,"score_spread":0.3843153765695846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}